vs
Side-by-side financial comparison of ORAMED PHARMACEUTICALS INC. (ORMP) and Alaunos Therapeutics, Inc. (TCRT). Click either name above to swap in a different company.
ORAMED PHARMACEUTICALS INC. produced more free cash flow last quarter ($-468.0K vs $-3.0M). Over the past eight quarters, Alaunos Therapeutics, Inc.'s revenue compounded faster (73.2% CAGR vs -100.0%).
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) immunotherapies for the treatment of hard-to-treat solid tumors. The firm focuses on advancing precision oncology candidates targeting shared tumor antigens, serving global oncology patient populations via internal R&D and cross-sector partnerships.
ORMP vs TCRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $3.0K |
| Net Profit | $10.0M | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | — | -40.0% |
| Net Profit YoY | 198.2% | -20.5% |
| EPS (diluted) | $0.25 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | $3.0K | ||
| Q3 25 | $0 | $0 | ||
| Q2 25 | $0 | $0 | ||
| Q1 25 | $2.0M | $2.0K | ||
| Q4 24 | — | $5.0K | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $4.0K | ||
| Q1 24 | — | $1.0K |
| Q4 25 | $10.0M | — | ||
| Q3 25 | $48.4M | $-1.2M | ||
| Q2 25 | $13.3M | $-1.1M | ||
| Q1 25 | $-7.6M | $-1.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-1.1M | ||
| Q2 24 | — | $-1.1M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -225.0% | -54600.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -29150.0% | ||
| Q1 24 | — | -174200.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -382.1% | -53650.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -28225.0% | ||
| Q1 24 | — | -168200.0% |
| Q4 25 | $0.25 | — | ||
| Q3 25 | $1.13 | $-0.55 | ||
| Q2 25 | $0.31 | $-0.63 | ||
| Q1 25 | $-0.19 | $-0.67 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.70 | ||
| Q2 24 | — | $-0.71 | ||
| Q1 24 | — | $-1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $51.4M | $1.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $199.7M | $2.2M |
| Total Assets | $230.9M | $3.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $51.4M | $1.4M | ||
| Q3 25 | $57.1M | $1.9M | ||
| Q2 25 | $17.6M | $2.9M | ||
| Q1 25 | $3.7M | $319.0K | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $4.1M |
| Q4 25 | $199.7M | $2.2M | ||
| Q3 25 | $203.3M | $2.8M | ||
| Q2 25 | $154.5M | $3.7M | ||
| Q1 25 | $140.8M | $1.1M | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | — | $2.7M | ||
| Q2 24 | — | $3.8M | ||
| Q1 24 | — | $4.8M |
| Q4 25 | $230.9M | $3.0M | ||
| Q3 25 | $220.5M | $3.7M | ||
| Q2 25 | $161.7M | $4.7M | ||
| Q1 25 | $147.5M | $2.1M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $4.7M | ||
| Q1 24 | — | $6.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-466.0K | $-2.9M |
| Free Cash FlowOCF − Capex | $-468.0K | $-3.0M |
| FCF MarginFCF / Revenue | — | -98900.0% |
| Capex IntensityCapex / Revenue | — | 3266.7% |
| Cash ConversionOCF / Net Profit | -0.05× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-466.0K | $-2.9M | ||
| Q3 25 | $-1.6M | $-844.0K | ||
| Q2 25 | $-3.5M | $-701.0K | ||
| Q1 25 | $-3.5M | $-772.0K | ||
| Q4 24 | — | $-5.0M | ||
| Q3 24 | — | $-781.0K | ||
| Q2 24 | — | $-1.7M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | $-468.0K | $-3.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-3.5M | — | ||
| Q1 25 | $-3.5M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -98900.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -176.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 3266.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | -0.05× | — | ||
| Q3 25 | -0.03× | — | ||
| Q2 25 | -0.27× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
